

13 March 2025

**Physiomics plc**  
**("Physiomics" or the "Company")**

**IMC Presentation on Company Website**

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update in-line with its Interim Results via *Investor Meet Company* and has updated its website with the presentation.

The presentation and Q&A from the meeting are now available at the Company's website:

<https://www.physiomics.co.uk/portfolio-item/investor-presentation-company-update-2/>

**Enquiries:**

**Physiomics plc**

Dr Jim Millen, Non-Executive Chairman  
Dr Peter Sargent, Chief Executive Officer  
+44 (0)1235 841575

**Hybridan LLP (Broker)**

Claire Louise Noyce  
+44 (0) 203 764 2341

**Strand Hanson Ltd (NOMAD)**

James Dance & James Bellman  
+44 (0)20 7409 3494

**Notes to Editor**

**About Physiomics**

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAEANDAFESSEFA